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1.	To	evaluate	the	utility	of	the	expression	of	interleukin-3	(IL-3)	in	
serum	 as	 a	 differential	 diagnosis	 tool	 in	 benign	 and	 malignant	
mammary	tumours.
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•More	IL-3	expression	in	benign	mammary	tumours
INFLAMMATION	AND	NEOPLASIAS
Figure	1:	Extrinsic	and	intrinsic	pathway	(Mantovani	et	al.	2008)
Figure	5:	Western	Blotting	results.	Marker	legend	and	radiograph	film
• Serum	samples	from	18	bitches	centrifugated	and	freezed	at	-80ºC.	
• Samples	 from	 Fundació	 Hospital	 Clínic	 Veterinari	 pacients	 with	 owners	
allowance.	
• Samples	analysis:	
• Bradford	method		
• Western	Blotting	(Figure	3	and	4).	Incubation	with	IL-3.
Figure	3:	Electrophoresis	preparation
Figure	4:	Membranes	incubation	with	
primary	antibody
•Tumor	 related	 with	 infections	 and	 chronic	
inflammation	in	25%	of	the	cases	
• Infections	 and	 chronic	 inflammations	 involved	 in	
tumoral	initiation,	promotion	and	progression	
• Cytokines	 improve	or	 inhibit	 tumoral	 growth	 and	 its	
progression	
•Inflammatory	interleukins	related	to	tumurogenesis
• Important	 role	 of	 interleukins	 in	 tumour	 growth	 as	 it	 is	 controlled	 by	
immune	system.	
• Tumoral	 microenvironment	 controlled	 by	 inflammatory	 cells,	 essential	
for	neoplasic	growth,	proliferation,	migration	and	survival.	
• IL-3	 might	 be	 implicated	 in	 antitumurogenic	 processes	 according	 to	
results	and	literature.	
• 	Might	IL-3	be	a	useful	serum	marker	for	diagnosis?	
• Further	studies	with	bigger	samples	need	to	be	done	
• Follow-up	 and	 periodical	 analysis	 and	 quantification	 of	 IL-3	 expression	
levels	in	serum	from	bitches	that	show	metastasis	as	a	possible	study
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